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1. Introduction  
First epidemiological studies of Lp(a) and CHD were reported at the end of the last century 
(1-3) but the investigation of this lipoprotein as a potential cardiovascular risk factor has 
been hampered by the lack of consistent approaches to its measurement for decades. Lp(a) 
laboratory standardization emerged in 2000 (4) and was accepted by the World Health 
Organization in 2004 (5). Another challenge associated to its measurement is the fact that 
population differences can also contribute to variation in Lp(a) serum concentration (6). 
Since Lp(a) characterization, evidences favoring its association with cardiovascular risk have 
been reported. At the same time, studies against this association have also been published 
leading to some confusion regarding to the possible role of Lp(a) in cardiovascular disease. 
The last years have clarified somewhat this issue and evidences of Lp(a) as an independent 
cardiovascular risk factor have been proposed (7-13). Several key points such as its 
homology with plasminogen, differences among the apo(a) isoforms, genetic considerations 
as well as special circumstances such as the relationship of Lp(a) and atrial fibrillation, 
dialysis, alcohol consumption and blood coagulation have been investigated. In this chapter, 
Lp(a) metabolism, epidemiological and genetic considerations, association with coronary 
heart disease and stroke, special situations as well as controversies and current treatment 
options are related.    
2. Lipoprotein (a) metabolism 
Lipoprotein (a), Lp (a), is a low density lipoprotein (LDL)-like particle synthesized in the 
liver by hepatocytes and then secreted into plasma. It was first described by Berg in 1963 
(14). It consists of an apolipoprotein B100 (apoB100) molecule that is linked covalently by a 
disulfide bond to a large glycoprotein known as apolipoprotein (a), [apo(a)] (15). Lp(a) 
metabolic route is shown in figure 1. Its molecular weight ranges from 200 kDa to more than 
800 kDa (16). The apo(a) gene (LPA) is a major determinant of the plasma concentration of 
Lp(a), including variations in the kringle region-coding repeats, with accounts for the size 
polymorphism of apo(a) leading to different apo(a) sizes (17). This fact is very important 
because small size isofoms seem to be associated to worse cardiovascular profile. Apo(a) 
chain contains 5 cysteine-rich domains known as kringles, and especially Kringle IV (KIV) is 
very similar to plasminogen (18,19). This particle is not only located in the plasma but also 
has been shown to enter the arterial intima of humans and has an increased affinity by the 
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extracellular matrix (20). This issue confers a greater opportunity to Lp(a) oxidation (21) and 
interaction of Lp(a) with macrophages (22,23). Recently, it has been suggested that Lp(a) 
could be a preferential carrier of oxidized phospholipids in human plasma (24). These 
oxidized Lp(a) have a greater atherosclerotic effect as compared to native Lp(a) and this 
action may be increased by hyperglucemia (25). Different Lp(a) subtypes have been 
proposed regarding to apo(a) isoforms and these apo(a) isoforms predict the risk for CHD 
independently of the ethnic group (26). These isoforms are classified in order to their 
different size (16). Table 1 shows classification of these isoforms and its relation with KIV 
repeats.     
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Fig. 1. Metabolic route of Lp(a). 
3. Epidemiological aspects 
Plasma levels of Lp(a) show great diversity regarding to different ethnical groups but a 
plasmatic concentration greater than 30 mg/dl is currently considered an independent 
cardiovascular risk factor (27). In this sense, African-Americans have higher Lp(a) 
concentrations than Caucasians. These levels may also be very different even in individuals 
carrying apo(a) of the same size polymorphism. It has been suggested the possibility of the 
presence of additional factors affecting this ethnical differences or the existence of high risk-
Lp(a) or low risk-Lp(a) (28,29). By the other hand, not all ethnic groups show the same 
relation with Lp(a). In American-Indians, Lp(a) level has been reported to be low and non 
independently associated with cardiovascular disease (30).     
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>700 >25
500-650 20-25
400-50013-20
<400 5-12
Molecular weight (kDa)Repeats (No.)
 
Table 1. Relation between KIV2  repeats and apo(a) isoforms size 
Respecting to apo(a) isofoms, it has been suggested a most important pathogenic role of Lp(a) 
particles with smaller apo(a) isoforms (18,31). This is probably due to several factors. First, an 
increased capacity to bind oxidized phospholipids, second, the ability to localize in blood 
vessel walls, and eventually related to its thrombogenic effect by increasing inhibition of 
plasmin activity. Apo(a) size heterogeneity is related to a copy number variation in the protein 
domain kringle IV type 2 (KIV2) (32) (Table 1). This copy number variation (5-50 identically 
repeated copies) confers heterogeneity in the molecular mass of apo(a) ranging between 200 
and 800 kDa. Ethnical differences in the frequency distribution of apo(a) KIV repeated alleles 
have been reported (33,34). In all ethnic groups, Caucasians, Asians and African-Americans, 
higher levels of circulating Lp(a) concentrations tend to be associated with smaller apo(a) 
isoforms (35,36). This finding could explain partially the association of higher Lp(a) levels and 
cardiovascular disease. People with smaller apo(a) isoforms have an approximately 2-fold 
higher risk of coronary artery disease and ischemic stroke than those with larger apo(a) 
isoforms. Furthermore, isoforms with less KIV repetitions (isoforms F, B, S1 and S2) have the 
greater analogy with plasminogen being associated with higher coronary risk (37,38).       
4. Genetic considerations 
Apo(a) gen (6q2.6-q2.7) (39,40) have different kringle domains that show a high degree of 
homology to the kringle domains IV and V of plasminogen (41). 
Genetic variants associated with Lp(a) level have been associated with coronary disease (42). 
More specifically, the apo(a) gen is the major determinant of variation in some populations 
like African-Americans modulating the plasmatic  concentration of Lp(a) (43). It has been 
reported that apo(a) gene accounts for greater than 90% of the variation of plasmatic Lp(a) 
concentrations (28). Apo(a) gen polymorphisoms as well certain gene cluster associated to 
LPA have been shown to modulate Lp(a) concentrations leading to an increase in the risk for 
coronary artery disease (44). The genetic basis for apo(a) isoform variation is a segment 
existing in multiple repeats (KIV2 polymorphism) located in the LPA gene (41). Variations in 
nucleotide polymorphisms in LPA may be an important contributor to the observed Lp(a) 
between-population variance and increase Lp(a) level in some populations (45-47). Once 
again, ethnical differences have been reported in people of European continental ancestry 
where apo(a) isoform polymorphism contributes between 40% and 70% of the variation of 
Lp(a) concentration showing fewer number of KIV2 repeats (41,46), (Table 1).     
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5. Evidences favoring association with cardiovascular disease 
- Coronary heart disease: Circulating Lp(a) concentration is associated with risk of 
coronary heart disease (CHD) independently from other conventional risk factors 
including total cholesterol concentration. Lp(a) excess has been independently 
associated to myocardial infarction and unstable angina (48), restenosis after coronary 
angioplasty (49), and coronary bypass grafting (50) respectively. Prospective 
epidemiological studies have reported positive association of baseline Lp(a) 
concentration with CHD risk . Based on this epidemiological data, a relative risk or 1.5 
has been reported involving those patients with mean Lp(a) values of 50 mg/dL, 
especially in patients with premature coronary disease (51). Continuous associations of 
Lp(a) with the risk of coronary artery  disease have been reported and this association is 
similar regarding to coronary death and non-fatal myocardial infarction (52-54). This 
association is not significantly affected by sex, non-HDL or HDL cholesterol, 
triglycerides, blood pressure, diabetes, of body mass index. These results are consistent 
mainly in Caucasians but studies in non-Caucasians are needed to corroborate also this 
issue in other populations (33). The association of Lp(a) concentrations with CHD is 
only slightly reduced after adjustment for long-term average levels of lipids and other 
established risk factors. This situation increases the likelihood that Lp(a) is an 
independent risk factor for CHD (53). The strength of Lp(a) as coronary risk factor is 
relatively modest as compared with non-HDL cholesterol. This is somewhat different 
when the level of Lp(a) is very high leading to a proportionally most important role for 
Lp(a) as CHD risk factor (52). Trying to associate fibrinolysis and myocardial ischemic 
disease, it has been suggested that Lp(a) may inhibit fibrinolysis of coronary artery 
thrombus (55). This is because higher levels of Lp(a) have been reported in survivors of 
myocardial infarction in whom recanalization of infarct artery failed as compared with 
patients with a patent artery (56). Other prospective studies have not shown 
relationship between high levels of Lp(a) or apo(a) isoforms and cardiovascular risk (57-
59) contributing to some degree of controversy.      
- Stroke: Serum Lp(a) concentration is also associated independently with risk of 
ischemic stroke (60,61). Current data in relation to Lp(a) concentration and stroke are 
sparse but seem to be similar than those for CHD. Serum Lp(a) level was demonstrated 
to predict stroke in elderly people in a large longitudinal (62) and in a case-control 
study (63). It has been shown that high levels of Lp(a) are associated with ischemic 
stroke in patients with atrial fibrillation especially when left atrial thrombus is present 
(64). Unhealthy dietary fat intake and a high serum Lp(a) level have been shown to 
predict fatal and nonfatal stroke of transient ischemic attack independently of 
established risk factors in a study of a community-based sample of middle-age men 
(65). Lp(a) has also been detected in intraparenchymal cerebral vessels suggesting a 
potential imflammatory role in acute stroke for Lp(a) (66). Other studies have not found 
statistical relationship between higher level of Lp(a) and thrombotic stroke (67).   
6. Special situations 
There are some common medical conditions that may be influenced by the level of Lp(a). 
Conversely, serum Lp(a) levels can be modified by the existence of some medical disorders. 
These medical conditions are summarized as follows: 
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- Lp(a) and dialysis: It is well known than atherosclerosis is more prevalent among 
patients with end-stage renal disease (68). Hemodialysis procedure “per se” has been 
shown to modify serum levels of Lp(a) increasing them after hemodialysis procedure 
(69). It has been proposed that inflammation, a very important condition in 
hemodialysis patients, could play an important role in this Lp(a) increase (70-72). Basal 
serum levels of Lp(a) are increased in dialysis patients and the level is elevated in 
almost 70% of patients (73). Even more, in patients with continuous ambulatory 
peritoneal dialysis, Lp(a) level is significantly higher as compared with patients on 
hemodialysis (74) pointing to a possible modulating effect of Lp(a) concentration by the 
different dialysis procedures. Particularly, high serum Lp(a) levels and the low 
molecular weight apo(a) phenotype have been associated with adverse clinical 
outcomes in dialysis patients (75).  
- Lp(a) and atrial fibrillation: Higher serum Lp(a) level in ischemic stroke patients 
associated with atrial fibrillation and left atrial thrombus formation or in acute 
myocardial infarction has been reported (76,77). Lp(a) elevation and reduced left atrial 
appendage flow velocities have been shown to be independently risk factors for 
thromboembolism in chronic nonvalvular atrial fibrillation (55). Probably, the 
association of Lp(a) is stronger in the presence of atrial thrombus instead of atrial 
fibrillation itself, because of the plasminogen inhibitory action of Lp(a) (64). In this 
sense, other studies have not found association between higher levels of Lp(a) and non-
valvular atrial fibrillation (78).    
- Lp(a) and blood coagulation: the genetic homology in the cDNA sequence of human 
apo(a) with plasminogen, the zymogen for the major fibrinolytic serine protease 
plasmin (79), has been related with the cardiovascular pathogenicity of Lp(a) (80). There 
is a major difference in the kringle structure between plasminogen and Lp(a) that is a 
single aminoacid exchange (R560S) that prevents apo(a) from enzymatic cleaveage such 
as the action of tissue-type plasminogen activator (t-PA) or urokinase plasminogen 
activator (u-PA). This molecular mimicry between plasminogen and Lp(a) contribute to 
the role of Lp(a) in atherogenesis binding Lp(a) to the tissue factor pathway inhibitor 
(TFPI), docking to diverse lipoprotein receptors (especially those affecting LDL or very 
low density lipoprotein (VLDL) and by the entrapment of Lp(a) into matricellular 
proteins (81). This situation leads to a retention of Lp(a) and recruitment of monocytes, 
upregulating the expression of the plasminogen activator inhibitor 2 in these monocytes 
(82). It has also been reported that Lp(a) modulates endothelial cell surface fibrinolysis 
contributing to the increase in atherosclerotic risk (83).  
- Lp(a) and alcohol intake: Many epidemiological and clinical studies have shown that 
light-to-moderate alcohol consumption is associated with reduced risk of CHD and 
total mortality in the middle-age and elderly of both genders (84,85). Lipid levels are 
modified by alcohol in different forms but it is not completely clear the way they are. In 
alcohol abuse patients, levels of Lp(a) have been reported to decrease and this has been 
related to the time of abstinence (86). In other study an increased level among table 
wine drinkers has been described (87). A special situation is the association of alcohol 
intake, Lp(a) level and vascular disease. In this sense, high serum Lp(a) concentration 
and heavy drinking were found independently associated with larger infrarenal aortic 
diameters (88) and abdominal aortic aneurysms (89), probably due to the capability of 
Lp(a) to inhibit elastolysis in the vessels wall (90).    
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7. Treatment  
Treatment possibilities are scarce at present when the aim is to reduce Lp(a) plasma 
concentration. Only niacin, in a dose dependent fashion, and certain inhibitors of cholesteryl 
ester transfer protein have shown limited effect ranging between 20%-40% lowering from 
baseline levels (91,92). Other drugs such as acetylsalicylic acid and L-carnitine can decrease 
mildly elevated Lp(a) concentrations (91,93,94). Contradictory findings have been reported 
with statins (95-98). Promising molecules like mipomersen, an antisense oligonucleotide 
directed to human apoB100 have been shown to reduce Lp(a) concentrations by 70% in 
transgenic mice (99). Similar molecules such as eprotirone, tibolone and proprotein 
convertase subtilisin/kexin type 9 (PCSK-9) inhibitors can also decrease Lp(a) 
concentrations being currently under development (91,100-102). Nevertheless, the most 
dramatic change in Lp(a) concentrations can be achieved with regular lipid apheresis 
(103,104). Table 2 shows the efficacy of different treatment options in reducing Lp(a) 
plasmatic level.  
40-60Apheresis
15-40Estrogen substitutive
therapy
25Neomicine
35Nicotinic acid
5Statins
5-10 Fibrates
0Resins
0Diet and exercise
Change in Lp(a) 
concentration (%)
Treatment
 
Table 2. Effect of different pharmacological therapies on Lp(a) serum concentration. 
8. Controversies 
The risk associated to Lp(a) concentration is only about one-quarter of that seen with LDL 
cholesterol so any clinical implication of this moderate association currently appeared 
limited. The role of specific Lp(a) subtypes could help to clarify the vascular risk. 
Particularly, smaller apo(a) isoforms could act associated with other factors such as small-
dense LDL and oxidized LDL particles in the vessel wall increasing inflammation and 
accelerating atherosclerotic disease. This fact needs for more investigation.  
Studies reporting association of apo(a) isoforms size variations with the risk of vascular 
disease have reported divergent relative risks, involve wide confidence intervals and the 
number of individuals included has been small. If smaller apo(a) isoforms are relevant to 
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vascular disease independent from Lp(a) concentration is not completely clear at present. 
Moreover, many studies have used different cut-offs to define smaller apo(a) size. 
The effect of the change in Lp(a) level and its relation with inflammation as well  as its 
influence on endothelial function are unknown at present.  
It has been suggested that Lp(a) is associated with CHD only at very high concentrations but 
this affirmation remains somewhat controversial making very important to identify possible 
ethnical differences as well as an adequate cut-off level we can rely on.   
9. Conclusions  
Lp(a) results from the association of apo(a) and LDL particles. Since first studies linking 
Lp(a) and cardiovascular disease, an important amount of clinical and laboratory evidences 
have supported the fact that Lp(a) is and independent cardiovascular risk factor, especially 
in younger people with premature cardiovascular disease.  
Many ethnical differences and variations in apo(a) size have been reported. Moreover, small 
apo(a) size isoforms have been related with an increased cardiovascular risk. Its relation 
with the number of KIV repeats determines genetically variation in apo(a) size. Several 
studies including methanalysis have related higher levels of Lp(a) with CHD and stroke.  
It seems also that Lp(a) is elevated in patients under dialysis, and possibly in those with 
atrial fibrillation increasing the cardiovascular risk of these patients, normally already high.    
An interesting link between laboratory and clinical effects of Lp(a) is its action modulating 
the fibrinolytic system because of the great homology between Lp(a) and plasminogen.  
The association between higher levels of Lp(a) and alcohol intake remains more 
controversial at present.  
Current treatment options are not very useful except for niacin and plasma apheresis but 
both therapies are not easy to use because of toxicity, tolerability and availability.  
Finally, large prospective studies are needed focusing on Lp(a)-associated small apo(a) 
isoforms and cardiovascular disease, and also in order to ensure treatment approaches.  
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